Claims extracted
18
sentences that state something as happening or true
Uncertain
11%
2 of 18 hedged
("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
63/100
Global News's corrections and
hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
10
Health
Same framing elsewhere
1
articles that frame the event the way this one does
GLP-1 drugs such as Ozempic and Wegovy prescribed in the U.S. will contain a new warning about a possible but rare side effect that can lead to permanent vision loss, the Food and Drug Administration (FDA) announced Monday.
asserted
Administration → prescribe → loss
The FDA will require the risk to be printed on the labelling of all GLP-1 drugs which are used to treat obesity, diabetes and a range of medical conditions, and can be injected or taken in pill form, including medications such as Zepbound and Mounjaro.
asserted
which → require → Zepbound
The “painless” eye condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), can cause significant vision loss as a result of decreased blood flow to the optic nerve; the FDA said the underlying cause is unknown.
asserted
cause → know → nerve
The labelling requirement stems from the findings of a 2024 study and subsequent FDA trials that tested the results of that study.
asserted
that → stem → study
An analysis of more than 125 clinical trials found that the problem occurred in roughly six of every 100,000 patients who took a GLP-1 for at least one year.
asserted
who → find → year
The agency also found reports of the problem in its electronic reporting system for drug injuries and side effects.
asserted
agency → find → injuries
The FDA concluded that there is a “potential increased risk of rare NAION events in patients taking GLP-1 RAs.”
“Based on these findings, FDA is requiring that application holders add information about the risk for NAION to the Warnings and Precautions section of labelling of all GLP-1 RAs,” it stated.
asserted
it → conclude → RAs
Symptoms of NAION include blurred vision, blind spots, distorted colours, and other visual irregularities, according to the U.S. regulator.
uncertain
Symptoms → include → regulator
Last month, Health Canada announced that it had identified a potential safety risk related to Ozempic, Rybelsus and Wegovy, citing NAION as the health issue under review.
asserted
it → announce → review
The findings of the review are yet to be published.
asserted
findings → publish → review
Canada operates under its own regulatory framework and sets labelling standards overseen by Health Canada and the Canadian Food Inspection Agency.
asserted
Canada → operate → Canada
Other studies published this year have linked the use of GLP-1s to outcomes such as reducing the risk of developing cancer.
asserted
studies → publish → cancer
Research presented alongside more than two dozen other studies at the American Society of Clinical Oncology in June found that patients taking GLP-1 drugs showed lower risks of developing cancer and disease progression, with better survival and improved responses to some treatments compared to people who were not taking the GLP-1s.
asserted
who → present → GLP-1s
Another observational study found that GLP’s can lead to an increased risk of hair loss in some patients.
asserted
GLP → find → patients
The British Medical Association study examined just over 50,000 people with Type 2 diabetes taking GLP-1 receptor stimulants and compared them with patients using other diabetes drugs such as SGLT-2 and DPP-4 inhibitors.
asserted
study → examine → inhibitors
The study says that GLP-1 usage was associated with a 37 per cent “higher risk of alopecia” compared with SGLT-2 inhibitors and a 68 per cent higher risk than those who use DPP-4 inhibitors.
asserted
who → say → inhibitors
A link to “non-scarring alopecia” with those who use GLP-1 drugs was also noted.
asserted
who → use → drugs
Actual rates of alopecia were low, ranging from roughly three to nine per 1,000 people per year, with between 11,000 and 15,000 people in each drug-class group.
“Although the absolute risk was small, awareness of this potential effect may support informed, patient-centred treatment decisions,” the study reads, though Dr. Elena Netchiporouk, Quebec’s regional director with the Canadian Dermatology Association, noted that hair loss might not be a result of the drug itself but rather the body losing weight too quickly.
uncertain
body → range → weight
The Aporia
